Published in Vaccine on November 05, 2009
Role of pore-forming toxins in bacterial infectious diseases. Microbiol Mol Biol Rev (2013) 1.91
Streptolysin S-like virulence factors: the continuing sagA. Nat Rev Microbiol (2011) 1.42
Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits. PLoS One (2011) 0.91
Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library. MAbs (2014) 0.91
Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells. Infect Immun (2011) 0.87
Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin. BMC Biotechnol (2011) 0.85
Identification of the factors that govern the ability of therapeutic antibodies to provide postchallenge protection against botulinum toxin: a model for assessing postchallenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare. J Pharmacol Exp Ther (2011) 0.83
Subunit vaccine efficacy against Botulinum neurotoxin subtypes. Vaccine (2011) 0.81
DNA vaccines targeting heavy chain C-terminal fragments of Clostridium botulinum neurotoxin serotypes A, B, and E induce potent humoral and cellular immunity and provide protection from lethal toxin challenge. Hum Vaccin Immunother (2015) 0.81
Antigen-expressing immunostimulatory liposomes as a genetically programmable synthetic vaccine. Syst Synth Biol (2010) 0.81
Enhancing the protective immune response against botulism. Infect Immun (2013) 0.81
Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D. PLoS One (2013) 0.81
Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication. Int Immunol (2011) 0.80
Inhalational botulism in rhesus macaques exposed to botulinum neurotoxin complex serotypes A1 and B1. Clin Vaccine Immunol (2010) 0.79
The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo. Clin Vaccine Immunol (2013) 0.78
Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo. Mol Ther Methods Clin Dev (2014) 0.78
Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors. Hum Vaccin Immunother (2014) 0.77
Preparation of egg yolk antibodies against BoNT/B and their passive protection in mouse models. Hum Vaccin Immunother (2014) 0.76
Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain. BMC Biotechnol (2015) 0.76
Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant. Hum Vaccin Immunother (2013) 0.75
Neutralization of Botulinum Neurotoxin Type E by a Humanized Antibody. Toxins (Basel) (2016) 0.75
Immunogenicity of a Trivalent Recombinant Vaccine Against Clostridium perfringens Alpha, Beta, and Epsilon Toxins in Farm Ruminants. Sci Rep (2016) 0.75
Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system. Hum Vaccin Immunother (2015) 0.75
Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism. Toxins (Basel) (2017) 0.75